$385.92 Million in Sales Expected for Amedisys Inc (NASDAQ:AMED) This Quarter
Equities research analysts expect Amedisys Inc (NASDAQ:AMED) to report $385.92 million in sales for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Amedisys’ earnings. The lowest sales estimate is $380.20 million and the highest is $390.87 million. Amedisys reported sales of $361.60 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 6.7%. The firm is expected to issue its next earnings results on Thursday, November 2nd.
According to Zacks, analysts expect that Amedisys will report full-year sales of $385.92 million for the current fiscal year, with estimates ranging from $1.51 billion to $1.54 billion. For the next fiscal year, analysts anticipate that the company will post sales of $1.61 billion per share, with estimates ranging from $1.60 billion to $1.63 billion. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Amedisys.
Amedisys (NASDAQ:AMED) last issued its earnings results on Wednesday, July 26th. The health services provider reported $0.62 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.50 by $0.12. The business had revenue of $378.80 million during the quarter, compared to analyst estimates of $380.80 million. Amedisys had a return on equity of 12.60% and a net margin of 3.16%. Amedisys’s revenue was up 5.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.42 EPS.
Several analysts have recently issued reports on AMED shares. Benchmark Co. reiterated a “hold” rating and issued a $57.00 price objective (up from $50.00) on shares of Amedisys in a research note on Wednesday, May 3rd. Zacks Investment Research cut Amedisys from a “buy” rating to a “hold” rating in a research note on Tuesday, May 2nd. Jefferies Group LLC reiterated a “buy” rating and issued a $57.00 price objective on shares of Amedisys in a research note on Friday, April 28th. Royal Bank Of Canada reiterated a “hold” rating and issued a $56.00 price objective on shares of Amedisys in a research note on Monday, June 5th. Finally, Mizuho upgraded Amedisys from a “neutral” rating to a “buy” rating and set a $65.00 price objective on the stock in a research note on Wednesday, May 3rd. Five equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $56.50.
In related news, insider Scott G. Ginn sold 23,828 shares of the firm’s stock in a transaction dated Monday, May 8th. The shares were sold at an average price of $58.62, for a total value of $1,396,797.36. Following the completion of the sale, the insider now owns 13,018 shares in the company, valued at $763,115.16. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Bruce D. Perkins acquired 500 shares of Amedisys stock in a transaction that occurred on Thursday, May 25th. The stock was purchased at an average price of $59.69 per share, with a total value of $29,845.00. Following the transaction, the director now owns 13,331 shares of the company’s stock, valued at $795,727.39. The disclosure for this purchase can be found here. In the last three months, insiders have sold 56,828 shares of company stock worth $3,350,922. Corporate insiders own 2.80% of the company’s stock.
A number of large investors have recently made changes to their positions in AMED. Great West Life Assurance Co. Can increased its stake in shares of Amedisys by 2.8% in the second quarter. Great West Life Assurance Co. Can now owns 41,182 shares of the health services provider’s stock worth $2,585,000 after buying an additional 1,120 shares during the last quarter. Municipal Employees Retirement System of Michigan increased its stake in shares of Amedisys by 3.5% in the second quarter. Municipal Employees Retirement System of Michigan now owns 6,590 shares of the health services provider’s stock worth $414,000 after buying an additional 220 shares during the last quarter. Boston Advisors LLC increased its stake in shares of Amedisys by 36.3% in the second quarter. Boston Advisors LLC now owns 39,377 shares of the health services provider’s stock worth $2,473,000 after buying an additional 10,489 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Amedisys during the second quarter worth approximately $3,697,000. Finally, Russell Investments Group Ltd. increased its stake in shares of Amedisys by 662.7% in the second quarter. Russell Investments Group Ltd. now owns 276,808 shares of the health services provider’s stock worth $17,387,000 after buying an additional 240,513 shares during the last quarter. Hedge funds and other institutional investors own 99.10% of the company’s stock.
Shares of Amedisys (NASDAQ:AMED) traded down 3.76% during midday trading on Thursday, reaching $46.86. The company’s stock had a trading volume of 1,939,138 shares. Amedisys has a one year low of $34.58 and a one year high of $65.91. The stock’s 50-day moving average is $61.28 and its 200-day moving average is $54.05. The company has a market capitalization of $1.58 billion, a P/E ratio of 34.71 and a beta of 0.94.
Amedisys Company Profile
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related stocks with our FREE daily email newsletter.